Networked in China

How small biotechs Ligand, Harbor BioSciences found partners in China

Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs looking to execute a China strategy. The key is personal networking.

In January, Ligand granted Chiva Pharmaceuticals Inc. rights to develop and commercialize HBV candidate pradefovir and liver cancer candidate MB01733 in China. Pradefovir has completed Phase II studies while MB01733 has completed a Phase

Read the full 613 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE